Does the media refer more to EWTX or MNKD?

In the previous week, Edgewise Therapeutics and Edgewise Therapeutics both had 8 articles in the media. Edgewise Therapeutics' average media sentiment score of 0.52 beat MannKind's score of 0.32 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TNGX or MNKD?

In the previous week, MannKind had 4 more articles in the media than Tango Therapeutics. MarketBeat recorded 8 mentions for MannKind and 4 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.59 beat MannKind's score of 0.32 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VKTX or MNKD?

In the previous week, Viking Therapeutics had 12 more articles in the media than MannKind. MarketBeat recorded 20 mentions for Viking Therapeutics and 8 mentions for MannKind. Viking Therapeutics' average media sentiment score of 0.60 beat MannKind's score of 0.32 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ABCL or MNKD?

In the previous week, AbCellera Biologics had 9 more articles in the media than MannKind. MarketBeat recorded 17 mentions for AbCellera Biologics and 8 mentions for MannKind. MannKind's average media sentiment score of 0.32 beat AbCellera Biologics' score of 0.07 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral MannKind 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, MNKD or TLX?

MannKind has higher earnings, but lower revenue than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MannKind $348.97M 3.50 $5.86M -$0.13 N/A Telix Pharmaceuticals $803.79M 4.46 -$7.12M N/A N/A

Is MNKD or TLX more profitable?

Telix Pharmaceuticals has a net margin of 0.00% compared to MannKind's net margin of -11.08%. Company Net Margins Return on Equity Return on Assets MannKind -11.08% N/A -6.31% Telix Pharmaceuticals N/A N/A N/A

Does the media prefer MNKD or TLX?

In the previous week, MannKind had 2 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 8 mentions for MannKind and 6 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.34 beat MannKind's score of 0.32 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Telix Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

MannKind (MNKD) Competitors

$3.80 -0.15 (-3.80%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.80 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Compare

MNKD vs. EWTX, TNGX, VKTX, ABCL, and TLX

Should you buy MannKind stock or one of its competitors? MannKind's main competitors and comparable companies include Edgewise Therapeutics (EWTX), Tango Therapeutics (TNGX), Viking Therapeutics (VKTX), AbCellera Biologics (ABCL), and Telix Pharmaceuticals (TLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MannKind compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and MannKind (NASDAQ:MNKD) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Edgewise Therapeutics has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, MannKind has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

49.6% of MannKind shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by insiders. Comparatively, 2.6% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Edgewise Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
MannKind	-11.08%	N/A	-6.31%

In the previous week, Edgewise Therapeutics and Edgewise Therapeutics both had 8 articles in the media. Edgewise Therapeutics' average media sentiment score of 0.52 beat MannKind's score of 0.32 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edgewise Therapeutics currently has a consensus target price of $51.33, indicating a potential upside of 23.99%. MannKind has a consensus target price of $8.34, indicating a potential upside of 119.57%. Given MannKind's higher probable upside, analysts clearly believe MannKind is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

MannKind has higher revenue and earnings than Edgewise Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
MannKind	$348.97M	3.50	$5.86M	-$0.13	N/A

Summary

MannKind beats Edgewise Therapeutics on 8 of the 15 factors compared between the two stocks.

How does MannKind compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and MannKind (NASDAQ:MNKD) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

In the previous week, MannKind had 4 more articles in the media than Tango Therapeutics. MarketBeat recorded 8 mentions for MannKind and 4 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.59 beat MannKind's score of 0.32 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by company insiders. Comparatively, 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tango Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market. Comparatively, MannKind has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

MannKind has higher revenue and earnings than Tango Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	62.82	-$101.59M	-$0.85	N/A
MannKind	$348.97M	3.50	$5.86M	-$0.13	N/A

Tango Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
MannKind	-11.08%	N/A	-6.31%

Tango Therapeutics presently has a consensus price target of $43.46, suggesting a potential upside of 87.01%. MannKind has a consensus price target of $8.34, suggesting a potential upside of 119.57%. Given MannKind's higher possible upside, analysts plainly believe MannKind is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Tango Therapeutics beats MannKind on 9 of the 16 factors compared between the two stocks.

How does MannKind compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and MannKind (NASDAQ:MNKD) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

MannKind has higher revenue and earnings than Viking Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
MannKind	$348.97M	3.50	$5.86M	-$0.13	N/A

Viking Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
MannKind	-11.08%	N/A	-6.31%

In the previous week, Viking Therapeutics had 12 more articles in the media than MannKind. MarketBeat recorded 20 mentions for Viking Therapeutics and 8 mentions for MannKind. Viking Therapeutics' average media sentiment score of 0.60 beat MannKind's score of 0.32 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viking Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, MannKind has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Viking Therapeutics currently has a consensus target price of $99.67, indicating a potential upside of 232.89%. MannKind has a consensus target price of $8.34, indicating a potential upside of 119.57%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Viking Therapeutics is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Viking Therapeutics beats MannKind on 10 of the 16 factors compared between the two stocks.

How does MannKind compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and MannKind (NASDAQ:MNKD) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

AbCellera Biologics has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, MannKind has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

AbCellera Biologics presently has a consensus price target of $13.38, suggesting a potential downside of 2.66%. MannKind has a consensus price target of $8.34, suggesting a potential upside of 119.57%. Given MannKind's higher possible upside, analysts plainly believe MannKind is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

MannKind has higher revenue and earnings than AbCellera Biologics. MannKind is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	56.07	-$146.41M	-$0.54	N/A
MannKind	$348.97M	3.50	$5.86M	-$0.13	N/A

61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by company insiders. Comparatively, 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, AbCellera Biologics had 9 more articles in the media than MannKind. MarketBeat recorded 17 mentions for AbCellera Biologics and 8 mentions for MannKind. MannKind's average media sentiment score of 0.32 beat AbCellera Biologics' score of 0.07 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
MannKind	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MannKind has a net margin of -11.08% compared to AbCellera Biologics' net margin of -248.83%. MannKind's return on equity of 0.00% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
MannKind	-11.08%	N/A	-6.31%

Summary

MannKind beats AbCellera Biologics on 9 of the 17 factors compared between the two stocks.

How does MannKind compare to Telix Pharmaceuticals?

MannKind (NASDAQ:MNKD) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

MannKind currently has a consensus target price of $8.34, suggesting a potential upside of 119.57%. Telix Pharmaceuticals has a consensus target price of $20.50, suggesting a potential upside of 94.31%. Given MannKind's higher possible upside, equities analysts clearly believe MannKind is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, MannKind had 2 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 8 mentions for MannKind and 6 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.34 beat MannKind's score of 0.32 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Telix Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

MannKind has higher earnings, but lower revenue than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.50	$5.86M	-$0.13	N/A
Telix Pharmaceuticals	$803.79M	4.46	-$7.12M	N/A	N/A

Telix Pharmaceuticals has a net margin of 0.00% compared to MannKind's net margin of -11.08%.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-11.08%	N/A	-6.31%
Telix Pharmaceuticals	N/A	N/A	N/A

MannKind has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.17, indicating that its share price is 117% less volatile than the broader market.

49.6% of MannKind shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

MannKind and Telix Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get MannKind News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNKD vs. The Competition

Export

Metric	MannKind	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.27B	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	16.77%
P/E Ratio	-29.23	12.93	273.75	26.04
Price / Sales	3.50	1,317.65	611.75	89.86
Price / Cash	63.83	122.60	77.60	51.75
Price / Book	-22.35	16.63	10.92	6.30
Net Income	$5.86M	-$22.67M	$3.50B	$361.43M
7 Day Performance	13.77%	-3.10%	-2.07%	-1.67%
1 Month Performance	-4.04%	-10.70%	-6.21%	-4.51%
1 Year Performance	-34.03%	19.46%	7.46%	2.03%

MannKind Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNKD MannKind	2.5281 of 5 stars	$3.80 -3.8%	$8.34 +119.6%	-30.8%	$1.27B	$348.97M	N/A	592
EWTX Edgewise Therapeutics	2.8446 of 5 stars	$39.79 +1.1%	$51.33 +29.0%	+176.0%	$4.27B	N/A	N/A	127
TNGX Tango Therapeutics	2.3741 of 5 stars	$24.30 -2.5%	$43.46 +78.9%	+202.2%	$4.20B	$62.38M	N/A	137	Gap Up
VKTX Viking Therapeutics	3.2341 of 5 stars	$33.03 -7.1%	$99.67 +201.7%	+7.4%	$4.15B	N/A	N/A	65
ABCL AbCellera Biologics	1.227 of 5 stars	$13.92 +9.6%	$12.86 -7.6%	+129.8%	$3.89B	$75.13M	N/A	562	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNKD) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MannKind (MNKD) Competitors

MNKD vs. EWTX, TNGX, VKTX, ABCL, and TLX

How does MannKind compare to Edgewise Therapeutics?

Summary

How does MannKind compare to Tango Therapeutics?

Summary

How does MannKind compare to Viking Therapeutics?

Summary

How does MannKind compare to AbCellera Biologics?

Summary

How does MannKind compare to Telix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD vs. The Competition

MannKind Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MannKind (MNKD) Competitors

MNKD vs. EWTX, TNGX, VKTX, ABCL, and TLX

How does MannKind compare to Edgewise Therapeutics?

Which has more risk & volatility, EWTX or MNKD?

Do insiders & institutionals believe in EWTX or MNKD?

Is EWTX or MNKD more profitable?

Does the media refer more to EWTX or MNKD?

Do analysts rate EWTX or MNKD?

Which has higher earnings and valuation, EWTX or MNKD?

Summary

How does MannKind compare to Tango Therapeutics?

Does the media refer more to TNGX or MNKD?

Do insiders & institutionals have more ownership in TNGX or MNKD?

Which has more volatility & risk, TNGX or MNKD?

Which has stronger earnings & valuation, TNGX or MNKD?

Is TNGX or MNKD more profitable?

Do analysts prefer TNGX or MNKD?

Summary

How does MannKind compare to Viking Therapeutics?

Which has higher earnings & valuation, VKTX or MNKD?

Is VKTX or MNKD more profitable?

Does the media refer more to VKTX or MNKD?

Which has more volatility and risk, VKTX or MNKD?

Do analysts prefer VKTX or MNKD?

Do insiders and institutionals believe in VKTX or MNKD?

Summary

How does MannKind compare to AbCellera Biologics?

Which has more volatility & risk, ABCL or MNKD?

Do analysts rate ABCL or MNKD?

Which has better earnings & valuation, ABCL or MNKD?

Do institutionals and insiders hold more shares of ABCL or MNKD?

Does the media refer more to ABCL or MNKD?

Is ABCL or MNKD more profitable?

Summary

How does MannKind compare to Telix Pharmaceuticals?

Do analysts recommend MNKD or TLX?

Does the media prefer MNKD or TLX?

Which has preferable earnings and valuation, MNKD or TLX?

Is MNKD or TLX more profitable?

Which has more volatility & risk, MNKD or TLX?

Do institutionals & insiders have more ownership in MNKD or TLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD vs. The Competition

MannKind Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools